Skip to main content
ELAN
NYSE Life Sciences

Elanco Reports Strong Q1 Results, Raises Full-Year Revenue, EBITDA, and EPS Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$22.99
Mkt Cap
$11.481B
52W Low
$9.42
52W High
$27.72
52W Position info
144% above low
Off High info
17% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ELAN has more than doubled off its 52-week low of $9.42.

Summary

Elanco Animal Health reported robust first-quarter results, exceeding expectations and leading the company to raise its full-year financial guidance across revenue, Adjusted EBITDA, and Adjusted EPS, while also improving its net leverage ratio target.


Key Events · Earnings and Guidance · ELAN

  • Strong Q1 Financial Performance

    Elanco reported first-quarter revenue of $1,371 million, a 15% increase year-over-year (10% organic constant currency growth), and Adjusted EPS of $0.40.

  • Raised Full-Year Guidance

    The company increased its full-year 2026 revenue guidance to $5.01 billion - $5.085 billion, Adjusted EBITDA to $975 million - $1.005 billion, and Adjusted EPS to $1.03 - $1.09.

  • Improved Leverage Target

    Elanco improved its year-end net leverage ratio target to 3.0x - 3.2x Adjusted EBITDA, indicating a strengthening financial position.

  • Innovation Success

    Key products like Zenrelia achieved trailing 4-quarter blockbuster status, and Credelio Quattro demonstrated accelerating market share gains.


Analysis · ELAN · Life Sciences

Elanco's first-quarter performance demonstrates significant operational momentum, with reported revenue increasing 15% year-over-year and organic constant currency growth of 10%. The company's decision to raise its full-year outlook for revenue, Adjusted EBITDA, and Adjusted EPS, alongside an improved year-end net leverage ratio target, signals strong confidence in its innovation-led strategy and financial health. This comprehensive "beat and raise" quarter, driven by new product success like Zenrelia and Credelio Quattro, suggests a positive trajectory for the company, especially following a net loss in the prior fiscal year. Investors should view this as a strong indicator of improving fundamentals and execution.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELAN was trading at $22.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $9.42 to $27.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAN - Latest Insights

ELAN
Nov 19, 2026, 6:35 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $27.45
Real-time Price: $25.81 info
Change: -$1.64 (-6%) info
Market Cap: $12.886B info
ELAN
Nov 06, 2026, 1:39 PM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $25.96
Real-time Price: $25.81 info
Change: -$0.150 (-0.58%) info
Market Cap: $12.886B info
ELAN
Nov 06, 2026, 9:10 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $24.32
Real-time Price: $25.81 info
Change: +$1.48 (+6%) info
Market Cap: $12.886B info
ELAN
Nov 06, 2026, 6:27 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.10
Real-time Price: $25.81 info
Change: +$1.70 (+7%) info
Market Cap: $12.886B info
ELAN
Nov 06, 2026, 6:27 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $24.10
Real-time Price: $25.81 info
Change: +$1.70 (+7%) info
Market Cap: $12.886B info